Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors - (AIs)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
- Enrollment
- 152
- Locations
- 1
- Primary Endpoint
- Adherence rate per the 8-item Morisky Medication Adherence Scale (MMAS - 8).
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
This is an observational trial designed to assess prospectively the adherence rate to AIs among women with invasive breast cancer (stages I-III) currently receiving AI adjuvant therapy after standard local and systemic therapy. We will study adherence by administrating the 8-item Morisky Medication Adherence Scale (MMAS - 8).
Detailed Description
* Women with breast cancer seen at the Texas Tech Physicians Breast Care Center will be recruited during their routine follow-up visit with their medical oncologist. * Post - menopausal women with histologically confirmed hormonal positive (ER and/or PR) invasive breast cancer stages I - III with no evidence of metastatic disease (M0). * Patients must be on one of AI (steroidal or non-steroidal). * Patient must have completed local treatment (surgery /radiation) and recovered from all side effects of chemotherapy and surgery. * Patient must be able to complete a demographic and the MMAS - 8 questionnaires in English or Spanish.
Investigators
Alexander Philipovskiy
Assistant Professor
Texas Tech University Health Sciences Center, El Paso
Eligibility Criteria
Inclusion Criteria
- •Post - menopausal women with histologically confirmed hormonal positive (ER and/or PR) invasive breast cancer stages I - III with no evidence of metastatic disease (M0).
- •Patient must have completed local treatment (surgery /radiation) and recovered from all side effects of chemotherapy and surgery.
- •Patient must be on one of AI (steroidal or non-steroidal).
- •Patient must be able to complete a demographic and the MMAS - 8 questionnaires in English or Spanish
Exclusion Criteria
- •\< 18 years old
Outcomes
Primary Outcomes
Adherence rate per the 8-item Morisky Medication Adherence Scale (MMAS - 8).
Time Frame: Every 6 months for up to 24 months
Primary endpoint of this study is to determine the adherence rate (high, medium and low) through the MMAS-8 among early stage breast cancer patients being treated at Texas Tech University Health Sciences Center El Paso (TTUHSC EP) where the majority of the patients are of Hispanic origin.